Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Amedica (AMDA) Competitors

Amedica logo

AMDA vs. PDEX, KRMD, CVRX, LUCD, LUNG, PROF, INFU, OBIO, ICAD, and MGRM

Should you be buying Amedica stock or one of its competitors? The main competitors of Amedica include Pro-Dex (PDEX), KORU Medical Systems (KRMD), CVRx (CVRX), Lucid Diagnostics (LUCD), Pulmonx (LUNG), Profound Medical (PROF), InfuSystem (INFU), Orchestra BioMed (OBIO), iCAD (ICAD), and Monogram Orthopaedics (MGRM).

Amedica vs.

Amedica (NASDAQ:AMDA) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.

Pro-Dex has a net margin of 11.06% compared to Amedica's net margin of -139.62%. Pro-Dex's return on equity of 21.68% beat Amedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Amedica-139.62% -148.60% -67.83%
Pro-Dex 11.06%21.68%12.40%

Amedica has a beta of -1.24, meaning that its stock price is 224% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

In the previous week, Pro-Dex had 2 more articles in the media than Amedica. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Amedica. Pro-Dex's average media sentiment score of 1.26 beat Amedica's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company Overall Sentiment
Amedica Neutral
Pro-Dex Positive

3.7% of Amedica shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 0.9% of Amedica shares are owned by insiders. Comparatively, 47.5% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amedica received 151 more outperform votes than Pro-Dex when rated by MarketBeat users. Likewise, 64.90% of users gave Amedica an outperform vote while only 61.90% of users gave Pro-Dex an outperform vote.

CompanyUnderperformOutperform
AmedicaOutperform Votes
307
64.90%
Underperform Votes
166
35.10%
Pro-DexOutperform Votes
156
61.90%
Underperform Votes
96
38.10%

Pro-Dex has higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedica$11.23M2.97-$9.32M-$3.13-0.90
Pro-Dex$64.12M2.32$2.13M$2.8016.29

Pro-Dex has a consensus price target of $52.00, indicating a potential upside of 13.99%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts clearly believe Pro-Dex is more favorable than Amedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Pro-Dex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Pro-Dex beats Amedica on 15 of the 18 factors compared between the two stocks.

Get Amedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMDA vs. The Competition

MetricAmedicaSurgical & Medical Instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$33.36M$4.43B$5.33B$8.39B
Dividend YieldN/A43.63%5.21%4.11%
P/E Ratio-0.9029.0826.7319.70
Price / Sales2.9770.54389.54120.67
Price / CashN/A51.0838.2534.62
Price / Book1.566.196.764.50
Net Income-$9.32M$67.60M$3.23B$248.22M

Amedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMDA
Amedica
N/A$2.81
-7.6%
N/A+3,229.7%$33.36M$11.23M-0.90N/ANews Coverage
Gap Down
High Trading Volume
PDEX
Pro-Dex
2.5748 of 5 stars
$43.34
+2.0%
$52.00
+20.0%
+132.2%$141.33M$64.12M21.56140Positive News
KRMD
KORU Medical Systems
2.3337 of 5 stars
$3.01
-6.2%
$4.50
+49.5%
+22.0%$138.88M$35.08M-12.0480
CVRX
CVRx
2.8408 of 5 stars
$5.29
-2.8%
$14.50
+174.1%
-22.0%$137.84M$51.29M-1.97160
LUCD
Lucid Diagnostics
3.1878 of 5 stars
$1.28
+7.6%
$3.50
+173.4%
+45.4%$134.89M$4.35M-1.1270Analyst Downgrade
Gap Down
High Trading Volume
LUNG
Pulmonx
3.2478 of 5 stars
$3.26
-1.8%
$12.07
+270.3%
-65.1%$131.24M$87.47M-2.26250Analyst Forecast
PROF
Profound Medical
2.5446 of 5 stars
$4.04
-5.4%
$11.50
+184.7%
-35.4%$121.41M$10.68M-3.01150
INFU
InfuSystem
2.4377 of 5 stars
$5.73
-0.3%
$13.00
+126.9%
N/A$120.42M$137.58M95.52410
OBIO
Orchestra BioMed
3.0369 of 5 stars
$2.82
-4.1%
$14.20
+403.5%
-48.5%$108.04M$2.64M-1.754Gap Up
ICAD
iCAD
0.3966 of 5 stars
$3.91
-0.5%
N/A+133.8%$107.31M$19.61M-30.08140Analyst Forecast
Gap Up
MGRM
Monogram Orthopaedics
3.0253 of 5 stars
$2.50
-3.5%
$5.40
+116.0%
+31.0%$88.22M$364,999.00-5.3228Gap Up

Related Companies and Tools


This page (NASDAQ:AMDA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners